Key Developments: Qiagen NV (QGEN.O)
19.46USD
17 Jun 2013
$0.35 (+1.83%)
$19.11
$19.38
$19.55
$19.26
529,142
718,709
$22.20
$15.90
Latest Key Developments (Source: Significant Developments)
SYGNIS Pharma AG Signs Distribution Agreement with QIAGEN NV
SYGNIS Pharma AG announced that it has signed a license agreement for the distribution of a new amplification buffer with QIAGEN NV. This is the second agreement with QIAGEN within 9 months and the first license agreement for the amplification buffer technology. Full Article
Qiagen NV Reaffirms FY 2013 Guidance-Conference Call
Qiagen NV announced that for fiscal 2013, it expects total net sales to rise about 5-6% and adjusted diluted earnings per share (EPS) to rise to approximately $1.16-1.18. The Company reported revenue of $1.25 billion in fiscal 2012. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of $1.33 billion for fiscal 2013. Full Article
WaferGen Bio Systems Inc And QIAGEN N.V's QIAGEN KK Sign Agreement For Co-Marketing in Japan
WaferGen Bio Systems Inc announced a co-marketing agreement with QIAGEN KK - a subsidiary of QIAGEN N.V.- for the joint promotion of certain products in Japan in the areas of genomics platforms such as Next-Gen sequencing (NGS) and qPCR. The purpose of the commercial relationship is to help life science researchers accelerate the process of developing markers that are potential candidates for molecular diagnostics by adding WaferGen's SmartChip solution to facilitate biomarker validation. Further customer-facing synergies will be achieved by offering QIAGEN's PCRarrays on the SmartChip and subsequently compatible NGS panels from QIAGEN. Full Article
Quiagen NV's Qiagen Marseille Sells Ipsogen Inc to Qiagen Inc
Qiagen NV's Qiagen Marseille announced it sold its subsidiary Ipsogen Inc. to Qiagen Inc. on January 1, 2013 for a global amount of USD 3.7 million. Full Article
Qiagen NV Issues FY 2013 Guidance Above Analysts' Estimates
Qiagen NV announced that for fiscal 2013, it expects total net sales to rise about 5-6% and adjusted diluted earnings per share (EPS) to rise to approximately $1.16-1.18. The Company reported revenue of $1.25 billion in fiscal 2012. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of $1.30 billion and EPS of $1.10 for fiscal 2013. Full Article
Qiagen NV Submits Companion Diagnostic To FDA To Guide Treatment Decisions For New Investigational Lung Cancer Compound
Qiagen NV announced submission of its therascreen EGFR RGQ PCR Kit (therascreen EGFR test) to the U.S. Food and Drug Administration (FDA) as a proposed companion diagnostic to guide treatment with afatinib, a new investigational oncology compound developed by Boehringer Ingelheim. Afatinib has been accepted for filing and granted Priority Review by the FDA as a proposed treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who havewith an epidermal growth factor receptor (EGFR) mutation detected by an FDA-approved test. QIAGEN submitted a Premarket Approval (PMA) application for use of the therascreen EGFR test to determine which NSCLC patients would be potentially eligible for treatment with afatinib. The companion diagnostic was developed in collaboration with Boehringer Ingelheim. In September 2012, the proposed drug also has been submitted to the European Medicines Agency (EMA). A version of the therascreen EGFR test has already been CE-marked and is available for diagnostic use in Europe. Full Article
Qiagen NV Confirms FY 2012 EPS Guidance
Qiagen NV announced that it confirms its outlook for the fiscal year 2012. It is expected that the adjusted diluted earnings per share for the fiscal year 2012 will increase to between USD 1.04 and USD 1.06. According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2012 earnings per share of USD 0.32. Full Article
Qiagen NV Announces Delay in Issuance of Q3 FY 2012 Report
Qiagen NV announced that it has decided to postpone the issuance of its report for third quarter and first nine months of the fiscal year 2012 due to the severe weather conditions in the United States and closing of U.S. stock exchanges due to Hurricane Sandy. The report is planned to be issued on November 4, 2012 at 18:00 Central European Time, 17:00 London time, 12:00 Eastern Standard Time. (Previously scheduled for October 29, 2012.) Full Article
Bayer AG’ HealthCare Unit And Qiagen NV To Collaborate On Cancer Therapies-DJ
Dow Jones reported that Bayer AG’ HealthCare Unit and Qiagen NV will collaborate on developing companion diagnostics to guide treatment decisions for specific cancer therapies. Financial details were not disclosed, but the agreement the two companies have signed provides the framework for further joint projects. The parties will also collaborate on the development of new technologies for patient profiling, which may result in research-use-only products for exploratory and translational medicine. Full Article
Qiagen NV Raises FY 2012 Guidance; Issues Q3 2012 EPS Guidance; Comments On Q3 2012 Revenue Guidance
Qiagen NV announced that for fiscal 2012, it expects net sales to rise approximately 8-9% CER, Adjusted diluted earnings per share (EPS) to rise to approximately $1.04-$1.06. For the third quarter of 2012, it expects net sales growth of approximately 9-10% CER and adjusted diluted EPS to be approximately $0.25. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $1.236 billion and EPS of $0.98 for fiscal 2012; revenue of $305.38 million and EPS of $0.25 for third quarter of 2012 Full Article
Qiagen buys genetic data processor Ingenuity for $105 million
FRANKFURT - Genetic testing specialist Qiagen NV said it bought privately held U.S. software developer Ingenuity Systems Inc for $105 million to expand further into genetic sequencing technology.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
